Newly approved drug effective against lung cancer caused by genetic mutation

(Washington University School of Medicine) The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news